XtalPi & CK Life Sciences Will Join Hands To Developing An AI-Powered Tumour Vaccine  

Yesterday, XtalPi revealed that they have begun a strategic partnership with CK Life Sciences, a part of the CK Hutchison Group. To enhance the discovery and design capabilities of tumour vaccines and speed up the development of more vaccine varieties, XtalPi and CK Life Sciences will combine their respective skills to establish a revolutionary AI tumour vaccine R&D platform. Precision therapy for patients around the world is the aim of this collaboration.

According to information accessible to the public, there were roughly 20 million newly diagnosed cancer patients globally in 2021, of which 4.5 million instances originated in China. Numerous cancer types result in unfavourable outcomes, have high morbidity and mortality rates, and yet have many unmet clinical needs. In order to trigger the patient's own specific immune responses, tumour vaccines targeting various cancer neoantigens, Tumour-Associated Antigens (TAA), and tumour-specific antigens (TSA) in patients can be created.

Currently, the U.S. Food and Drug Administration has only licenced two therapeutic tumour vaccines, sipuleucel-T for melanoma and Bacillus Calmette-Guérin (BCG) for bladder cancer, as well as preventative tumour vaccines against hepatitis B and the human papillomavirus (FDA). Other-tumour vaccines have recently begun to undergo clinical trials, and efficacy data is starting to accumulate.

The global market for cancer vaccines was valued at US$6.79 billion in 2021, and Mordor Intelligence projects that it will expand at a compound annual growth rate of 11.53% from 2022 to 2026. By 2026, a market worth about $12 billion is anticipated.